Collecting data on immune-related side effects in cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Montreal Immune-Related Adverse Events (MIRAE) study aims to gather clinical information and biological samples from cancer patients undergoing treatment with immune checkpoint inhibitors (ICIs). This observational study focuses on understanding the causes and identifying predictive biomarkers for immune-related adverse events (irAEs), which can range from mild to severe and may lead to treatment discontinuation. By analyzing these samples, researchers hope to develop effective management strategies for irAEs and improve patient outcomes in cancer therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \>= 18 years of age
* cancer patients treated with ICI therapy (e.g., anti-CTLA-4, anti-PD-1, anti-PD-L1, and combinations)
* patients with primary autoimmune or autoinflammatory diseases that resemble immune-related adverse events (irAEs)
* healthy volunteers with non-inflammatory disorders, and without any history of cancer

Exclusion Criteria:

* Participants not able to provide informed consent

Where it's running

• Jewish General Hospital
  Montreal, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Marie Hudson, MD — Jewish General Hospital, McGill University
• Study coordinator: Marie Hudson, MD
• Email: marie.hudson@mcgill.ca, marie.hudson.med@ssss.gouv.qc.ca
• Phone: 1-514-340-8222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• Music-4-MS: A 12-week music-based program to support thinking skills in people with MS

  A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.

  Recruiting University of Texas at Austin · Austin, Texas · NCT07759115

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• AMX0035 in adults with Type 1 Diabetes

  This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.

  Recruiting Phase 2 University of Washington · Seattle, Washington and 1 other locations · NCT07699380

• CD19/BCMA UCART for B cell–related autoimmune diseases

  This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07586267

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.